Global Monoclonal antibodies (mAbs) Biosimilars Industry Research Report, Growth Trends and Competitive Analysis 2024-2034
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Monoclonal antibodies (mAbs) Biosimilars Industry Research Report, Growth Trends and Competitive Analysis 2024-2034
A biosimilar medicine is a medicinal product of biological origin that is produced in a living organism following a procedure equivalent to a biological drug and adhering to the same quality criteria, hence the name biosimilars. In short, they are biological drugs that are “equivalent” in terms of quality, efficacy and safety to an innovative reference medicinal product.
Due to the COVID-19 pandemic, the global Monoclonal antibodies (mAbs) Biosimilars market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Erythropoietin (EPO) accounting for % of the Monoclonal antibodies (mAbs) Biosimilars global market in 2022, is projected to value US$ million by 2034, growing at a revised % CAGR from 2024 to 2034. While Anti-Cancer segment is altered to an % CAGR throughout this forecast period.
According to the report, one driver that will lead to the growth of this market is the rise in number of patent expiries.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Monoclonal antibodies (mAbs) Biosimilars market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Monoclonal antibodies (mAbs) Biosimilars market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Monoclonal antibodies (mAbs) Biosimilars market. Readers of the report can become informed about current and future trends of the global Monoclonal antibodies (mAbs) Biosimilars market and how they will impact market growth during the forecast period.
Biocon
Celltrion
Dr. Reddy's Laboratories
Hospira
3SBio
Accord Healthcare
AET Biotech
Allergan
Amega Biotech
Segment by Type
Erythropoietin (EPO)
Human Growth Hormone (HGH)
Granulocyte- Colony Stimulating Factor (G-CSF)
Monoclonal Antibody (mAb)
Insulin
Interferon (IFN)
Others
Anti-Cancer
Anti-Inflammatory/Autoimmune
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on.
Chapter 2Revenue of Monoclonal antibodies (mAbs) Biosimilars in global and regional level.
Chapter 3Detailed analysis of Monoclonal antibodies (mAbs) Biosimilars companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8Asia Pacific by type, by application and by region, revenue for each segment.
Chapter 9Latin America by type, by application and by country, revenue for each segment.
Chapter 10Middle East and Africa, by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Monoclonal antibodies (mAbs) Biosimilars revenue, gross margin, and recent development, etc.
Chapter 12Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 13Research Findings and Conclusion
Due to the COVID-19 pandemic, the global Monoclonal antibodies (mAbs) Biosimilars market size was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2034 with a CAGR of % during the forecast period 2024-2034. Fully considering the economic change by this health crisis, Erythropoietin (EPO) accounting for % of the Monoclonal antibodies (mAbs) Biosimilars global market in 2022, is projected to value US$ million by 2034, growing at a revised % CAGR from 2024 to 2034. While Anti-Cancer segment is altered to an % CAGR throughout this forecast period.
According to the report, one driver that will lead to the growth of this market is the rise in number of patent expiries.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Monoclonal antibodies (mAbs) Biosimilars market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Monoclonal antibodies (mAbs) Biosimilars market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Monoclonal antibodies (mAbs) Biosimilars market. Readers of the report can become informed about current and future trends of the global Monoclonal antibodies (mAbs) Biosimilars market and how they will impact market growth during the forecast period.
By Company
Biocon
Celltrion
Dr. Reddy's Laboratories
Hospira
3SBio
Accord Healthcare
AET Biotech
Allergan
Amega Biotech
Segment by Type
Erythropoietin (EPO)
Human Growth Hormone (HGH)
Granulocyte- Colony Stimulating Factor (G-CSF)
Monoclonal Antibody (mAb)
Insulin
Interferon (IFN)
Others
Segment by Application
Anti-Cancer
Anti-Inflammatory/Autoimmune
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on.
Chapter 2Revenue of Monoclonal antibodies (mAbs) Biosimilars in global and regional level.
Chapter 3Detailed analysis of Monoclonal antibodies (mAbs) Biosimilars companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6North America (US & Canada) by type, by application and by country, revenue for each segment.
Chapter 7Europe by type, by application and by country, revenue for each segment.
Chapter 8Asia Pacific by type, by application and by region, revenue for each segment.
Chapter 9Latin America by type, by application and by country, revenue for each segment.
Chapter 10Middle East and Africa, by type, by application and by country, revenue for each segment.
Chapter 11Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Monoclonal antibodies (mAbs) Biosimilars revenue, gross margin, and recent development, etc.
Chapter 12Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 13Research Findings and Conclusion
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices